Gates Foundation Strategic Investment Fund Logo
Share this page:


									Achaogen Logo

Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation’s investment is supporting the development of Achaogen’s monoclonal antibody (“mAb”) discovery platform. The foundation is currently working with the company to discover prophylactic mAb candidates targeting Acinetobacter baumannii, a leading cause of neonatal sepsis, which leads to approximately 345,000 annual deaths globally.

Investment Date: May 2017

Press Release